Osteocalcin Protects Against Nonalcoholic Steatohepatitis in a Mouse Model of Metabolic Syndrome
Authors:
- Anisha A. GupteAGAnisha A. Gupte
- Omaima M. SabekOSOmaima M. Sabek
- Solmaz AfsharSASolmaz Afshar
- Willa A. HsuehWHWilla A. Hsueh
- 1 December 2014
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 155 (12) , 4697-4705
Abstract
Nonalcoholic fatty liver disease, particularly its more aggressive form, nonalcoholic steatohepatitis (NASH), is associated with hepatic insulin resistance. Osteocalcin, a protein secreted by osteoblast cells in bone, has recently emerged as an important metabolic regulator with insulin-sensitizing properties. In humans, osteocalcin levels are inversely associated with liver disease. We thus hypothesized that osteocalcin may attenuate NASH and examined the effects of osteocalcin treatment in middle-aged (12-mo-old) male Ldlr−/− mice, which were fed a Western-style high-fat, high-cholesterol diet for 12 weeks to induce metabolic syndrome and NASH. Mice were treated with osteocalcin (4.5 ng/h) or vehicle for the diet duration. Osteocalcin treatment not only protected against Western-style high-fat, high-cholesterol diet-induced insulin resistance but substantially reduced multiple NASH components, including steatosis, ballooning degeneration, and fibrosis, with an overall reduction in nonalcoholic fatty liver disease activity scores. Further, osteocalcin robustly reduced expression of proinflammatory and profibrotic genes (Cd68, Mcp1, Spp1, and Col1a2) in liver and suppressed inflammatory gene expression in white adipose tissue. In conclusion, these results suggest osteocalcin inhibits NASH development by targeting inflammatory and fibrotic processes.Keywords
This publication has 39 references indexed in Scilit:
- The Relationship between Serum Osteocalcin Concentration and Glucose Metabolism in Patients with Type 2 Diabetes MellitusInternational Journal of Endocrinology, 2013
- Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolismJournal of Clinical Investigation, 2012
- Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in miceBone, 2012
- Rosiglitazone Attenuates Age- and Diet-Associated Nonalcoholic Steatohepatitis in Male Low-Density Lipoprotein Receptor Knockout MiceHepatology, 2010
- Review: Advances in the treatment of nonalcoholic fatty liver diseaseTherapeutic Advances in Endocrinology and Metabolism, 2010
- Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid ObesityDiabetes, 2009
- Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in miceJournal of Clinical Investigation, 2007
- Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the wayDiabetologia, 2006
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005